<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280367</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191093</org_study_id>
    <secondary_id>2019-A02663-54</secondary_id>
    <nct_id>NCT04280367</nct_id>
  </id_info>
  <brief_title>Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age</brief_title>
  <acronym>DYS FUTURS UHR</acronym>
  <official_title>Childhood Learning and Executive Function Disorders and Risk of Psychosis in the Adulthood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study aims to study transition toward schizophrenia in patients
      with learning disorders, and to compare the risk between patients with specific learning
      disorders, and patients with complexed learning disorders (by two types: patients with other
      neuro-developmental disorders including executive function disorders, and patients with
      anxiety).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As secondary objectives, the study aims to:

        -  argue the clinical predicted markers (neuropsychological) transition toward psychosis.

        -  test the feasibility and the acceptability of a early diagnosis for a potential
           applicable guidance for different referent centers of learning in French territory.

        -  have a better classification of patients with learning disorders in order to target a
           prospective primary prevention of risk of psychosis via the questionnaires (AQ of
           Baron-Cohen: Autism-spectrum quotient auto-questionnaire; Inventory of Beck Anxiety
           Inventory, auto-questionnaire for panic disorder and general anxiety; Liebowitz Social
           Anxiety Scale).

        -  improve identification of the early signs and the early emerging psychological diseases
           intervention management (schizophrenia).

        -  Psychic disability: prevent and reduce non-seeking care and accompaniment situations,
           and risk of rupture of care.

        -  permitting better care of psychosocial rehabilitation with cognitive evaluation.

      This study will be conducted in Centre de référence des troubles du langage et des
      apprentissages, Hôpital Raymond Poincaré, APHP, in France.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Semi-structured interview</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessement with Comprehensive Assessment of At-Risk Mental States (CAARMS) during 6 to 90 minutes at the center of Raymond Poincaré hospital.
The unique collection during the interview, quotation of each patient will be given from the assessement.
There will be 4 groups by the results: CAARMS negative subjects, vulnerable subjects, attenuated psychosis subjects and subjects with brief and limited intermittent psychotic syndrome. The further statistic comparison will be done between the 3 last groups classified with results of CAARMS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autistic screening</measure>
    <time_frame>At baseline</time_frame>
    <description>Autism-spectrum quotient (AQ) auto-questionnaire will be used to evaluate difficulty in social interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety measuring</measure>
    <time_frame>At baseline</time_frame>
    <description>An inventory for measuring clinical anxiety: Beck Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social interaction difficulty evaluation</measure>
    <time_frame>At baseline</time_frame>
    <description>Liebowitz Social Anxiety Scale as questionnaire</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Learning Disorders</condition>
  <condition>Executive Function Disorders</condition>
  <arm_group>
    <arm_group_label>Comparator group</arm_group_label>
    <description>Specific learning disorders group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neuro-developmental complexed group</arm_group_label>
    <description>Group of neuro-developmental complexe of learning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Complexed with anxiety</arm_group_label>
    <description>Disorders in learning with anxiety</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standardised semi-structured talk</intervention_name>
    <description>Comprehensive assessment of at-risk mental states (CAARMS) will be used.</description>
    <arm_group_label>Comparator group</arm_group_label>
    <arm_group_label>Complexed with anxiety</arm_group_label>
    <arm_group_label>neuro-developmental complexed group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Autistic spectre disorder screening</intervention_name>
    <description>Autism-spectrum quotient (AQ) auto-questionnaire will be used.</description>
    <arm_group_label>Comparator group</arm_group_label>
    <arm_group_label>Complexed with anxiety</arm_group_label>
    <arm_group_label>neuro-developmental complexed group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Anxiety measuring</intervention_name>
    <description>An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.</description>
    <arm_group_label>Comparator group</arm_group_label>
    <arm_group_label>Complexed with anxiety</arm_group_label>
    <arm_group_label>neuro-developmental complexed group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients between 15 and 30 years, suffering learning disorders complicated with two orders:
        with other neuro-developmental, or with anxiety (vs specific: comparator group).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients born between 1990 and 2005, have been cared by Dr Schlumberger in 2014 in the
             center of language and learning disorders at Raymond Poincaré hospital;

          -  With severe learning disorders: deficiency in school work, need at least one medical
             appointment and long-term rehabilitation in the center of language and learning
             disorders at Raymond Poincaré hospital;

          -  Affiliated to a social protection schema;

          -  Written informed consent signed.

        Exclusion Criteria:

          -  Absence of learning disorder;

          -  Intellectual deficiency;

          -  Epilepsia;

          -  Patients who will performed follow-up at Chartres city;

          -  Patients under guardianship or curatorship;

          -  Foreign patients under AME schema, a medical help from the state in France.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie SCHLUMBERGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albane Mansoux</last_name>
    <role>Study Director</role>
    <affiliation>Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie SCHLUMBERGER, MD</last_name>
    <phone>+33 1 47 10 46 13</phone>
    <email>emilie.schlumberger@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>learning disorders</keyword>
  <keyword>executive function disorders</keyword>
  <keyword>psychosis</keyword>
  <keyword>children</keyword>
  <keyword>adult-age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Learning Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

